SYMJEPI® (epinephrine) Injection is indicated for the emergency treatment of allergic reactions (Type 1- including anaphylaxis) to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances and other allergens, as well as idiopathic or exercise-induced anaphylaxis.
SYMJEPI 0.15mg is intended for immediate administration in patients who weigh 33 to 66 pounds; SYMJEPI 0.3mg is intended for immediate administration in patients who weigh 66 pounds or more and who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions.
Want to learn more?
Read our press release go to our Investor Relations page or visit https://dmkpharma.com/
Check this page for the most recent updates regarding the merger process.